A Clinical Study of SHR-3276 for Injection in Patients With Advanced Malignant Tumors
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3276 for injection in patients with advanced solid tumors.
Advanced Solid Tumors
DRUG: SHR-3276
Incidence and severity of adverse events, up to 3 years|MTD, up to 6 months|RP2D, up to 1 year
Time to maximum concentration (Tmax), up to 3 years|Maximum concentration (Cmax), up to 3 years|Receptor Occupancy（OR） of SHR-3276, up to 3 years|Anti-drug antibody (ADA) of SHR-3276, up to 3 years|Objective response rate (ORR), From date of administration until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years|Duration of response (DoR), From date of administration until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years|Disease control rate (DCR), From date of administration until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years|Progression free survival（PFS）, From date of administration until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years|Overall survival (OS), From date of administration until the date of first documented progression or date of death from any cause, whichever came first, up to 3 years
This study is an open-label, multicenter Phase I/II clinical trial to evaluate the safety, tolerability, pharmacokinetics and efficacy of SHR-3276 for injection in patients with advanced solid tumors.